Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: A cohort analysis from Uganda

Annals of Internal Medicine

Volumn 155, Issue 4, 2011, Pages 209-217

  Mills, Edward J ^a   Bakanda, Celestin ^b   Birungi, Josephine ^b   Chan, Keith ^c   Ford, Nathan ^d   Cooper, Curtis L ^e   Nachega, Jean B ^f   Dybul, Mark ^g   Hogg, Robert S ^c  

^a UNIVERSITY OF OTTAWA   (Canada)

^b THE AIDS SUPPORT ORGANIZATION   (Uganda)

^c BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^d M decins Sans Frontières   (Switzerland)

^e UNIVERSITY OF OTTAWA   (Canada)

^f JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^g GEORGETOWN UNIVERSITY LAW CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGE DISTRIBUTION; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DEVELOPING COUNTRY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROSPECTIVE PAYMENT; SEX DIFFERENCE; UGANDA;

EID: 80051603184     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-155-4-201108160-00358     Document Type: Article

References (45)

1. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al; Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006; 367:817-24. [PMID: 16530575]
2. Brinkhof MW, Boulle A, Weigel R, Messou E, Mathers C, Orrell C, et al; International Epidemiological Databases to Evaluate AIDS (IeDEA). Mortality of HIV-infected patients starting antiretroviral therapy in sub-Saharan Africa: comparison with HIV-unrelated mortality. PLoS Med. 2009;6:e1000066. [PMID: 19399157]
3. Kuwane B, Appiah K, Felix M, Grant A, Churchyard G. Expanding HIV care in Africa: making men matter in Johannesburg [Letter]. Lancet. 2009;374: 1329. [PMID: 19837252]
4. Leisegang R, Cleary S, Hislop M, Davidse A, Regensberg L, Little F, et al. Early and late direct costs in a Southern African antiretroviral treatment programme: a retrospective cohort analysis. PLoS Med. 2009;6:e1000189. [PMID: 19956658]
5. Madhavan S, Schatz E, Clark B. Effect of HIV/AIDS-related mortality on household dependency ratios in rural South Africa, 2000-2005. Popul Stud (Camb). 2009;63:37-51. [PMID: 19184720]
6. McGuire AL, Barer JM, Montaner JS, Hogg RS. There and back again: the impact of adult HIV prevalence on national life expectancies [Letter]. HIV Med. 2005;6:57-8. [PMID: 15807710]
7. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372:293-9. [PMID: 18657708]
8. Braitstein P, Boulle A, Nash D, Brinkhof MW, Dabis F, Laurent C, et al; Antiretroviral Therapy in Lower Income Countries (ART-LINC) Study Group. Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration. J Womens Health (Larchmt). 2008;17:47-55. [PMID: 18240981]
9. Rosen S, Fox MP, Gill CJ. Patient retention in antiretorviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med. 2007;8:267-70.
10. Tam LW, Hogg RS, Yip B, Montaner JS, Harrigan PR, Brumme CJ. Performance of a World Health Organization first-line regimen (stavudine/lamivudine/ nevirapine) in antiretroviral-nai{dotless}̈ve individuals in a Western setting. HIV Med. 2007;8:267-70. [PMID: 17561871]
11. Cooper CL, Mills E, Wabwire BO, Ford N, Olupot-Olupot P. Chronic viral hepatitis may diminish the gains of HIV antiretroviral therapy in sub- Saharan Africa. Int J Infect Dis. 2009;13:302-6. [PMID: 19004656]
12. Harries AD, Boxshall M, Phiri S, Kwanjana J. Managing HIV and tuberculosis in sub-Saharan Africa [Letter]. Lancet. 2006;367:1817-8. [PMID: 16753481]
13. WHO Global Health Observatory 2008, Uganda. Accessed at http://apps.who.int/ghodata/?vid_720 on 28 February 2011
14. Katabira E, Kamya MR, Kalyesubula I, Namale A. Uganda Ministry of Health. National Antiretroviral Treatment Guidelines for Adults, Adolescents, and Children. 3rd ed. 2009. Accessed at www.idi.ac.ug/docs/guidelines%202009.pdf
15. WHO antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach. Accessed at www.who.int/hiv /pub/guidelines/adult/en/index.htmlon 27 February 2011
16. Kiboneka A, Wangisi J, Nabiryo C, Tembe J, Kusemererwa S, Olupot-Olupot P, et al. Clinical and immunological outcomes of a national paediatric cohort receiving combination antiretroviral therapy in Uganda. AIDS. 2008;22: 2493-9. [PMID: 19005272]
17. Kiboneka A, Nyatia RJ, Nabiryo C, Anema A, Cooper CL, Fernandes KA, et al. Combination antiretroviral therapy in population affected by conflict: outcomes from large cohort in northern Uganda. BMJ. 2009;338:b201. [PMID: 19223338]
18. Mills EJ, Bakanda C, Birungi J, Mwesigwa R, Chan K, Ford N, et al. Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: evidence from a large cohort in Uganda. AIDS. 2011;25:851-5. [PMID: 21330903]
19. Bakanda C, Birungi J, Mwesigwa R, Zhang W, Hagopian A, Ford N, et al. Density of healthcare providers and patient outcomes: evidence from a nationally representative multi-site HIV treatment program in Uganda. PLoS One. 2011; 6:e16279. [PMID: 21264224]
20. Kiboneka A, Nyatia RJ, Nabiryo C, Anema A, Cooper CL, Fernandes KA, et al. Combination antiretroviral therapy in population affected by conflict: outcomes from large cohort in northern Uganda. BMJ. 2009;338:b201. [PMID: 19223338]
21. Kiboneka A, Wangisi J, Nabiryo C, Tembe J, Kusemererwa S, Olupot- Olupot P, et al. Clinical and immunological outcomes of a national paediatric cohort receiving combination antiretroviral therapy in Uganda. AIDS. 2008;22: 2493-9. [PMID: 19005272]
22. Bakanda C, Birungi J, Nkoyooyo A, Featherstone A, Cooper CL, Hogg RS, et al. Cohort Profile: The TASO-CAN Cohort Collaboration. Int J Epidemiol. 2011. [PMID: 21382975]
23. Bakanda C, Birungi J, Mwesigwa R, Ford N, Cooper CL, Au-Yeung C, et al. Association of aging and survival in a large HIV-infected cohort on antiretroviral therapy. AIDS. 2011;25:701-5. [PMID: 21160412]
24. Amuron B, Namara G, Birungi J, Nabiryo C, Levin J, Grosskurth H, et al. Mortality and loss-to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda. BMC Public Health. 2009;9:290. [PMID: 19671185]
25. Geng EH, Emenyonu N, Bwana MB, Glidden DV, Martin JN. Samplingbased approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa [Letter]. JAMA. 2008;300:506-7. [PMID: 18677022]
26. Romeder JM, McWhinnie JR. Potential years of life lost between ages 1 and 70: an indicator of premature mortality for health planning. Int J Epidemiol. 1977;6:143-51. [PMID: 892979]
27. Allison PD. Survival Analysis Using the SAS System: A Practical Guide. Cary, NC: SAS Institute; 1995.
28. Chiang CL. On constructing current life tables. J Am Stat Assoc. 1972;67: 538-41.
29. Chiang CL. The Life Table and Its Construction. Introduction to Stochastic Processes in Biostatistics. New York: J Wiley; 1968:189-214.
30. Eayres D, Williams ES. Evaluation of methodologies for small area life expectancy estimation. J Epidemiol Community Health. 2004;58:243-9. [PMID: 14966240]
31. Williams T, Dinsdale H, Eayres D, Tahzib F. South East Public Health Observatory. Technical Report. Calculating Life Expectancy in small areas. Accessed at www.sepho.org.uk/Download/Public/9847/1/Life%20Expectancy %20Nov%2005.pdf on 28 February 2011
32. Lima VD, Hogg RS, Harrigan PR, Moore D, Yip B, Wood E, et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS. 2007;21:685-92. [PMID: 17413689]
33. Fang CT, Chang YY, Hsu HM, Twu SJ, Chen KT, Lin CC, et al. Life expectancy of patients with newly-diagnosed HIV infection in the era of highly active antiretroviral therapy. QJM. 2007;100:97-105. [PMID: 17277317]
34. Muula AS, Ngulube TJ, Siziya S, Makupe CM, Umar E, Prozesky HW, et al. Gender distribution of adult patients on highly active antiretroviral therapy (HAART) in Southern Africa: a systematic review. BMC Public Health. 2007;7: 63. [PMID: 17459154]
35. Mills EJ, Ford N, Mugyenyi P. Expanding HIV care in Africa: making men matter. Lancet. 2009;374:275-6. [PMID: 19632481]
36. Nachega JB, Hislop M, Nguyen H, Dowdy DW, Chaisson RE, Regensberg L, et al. Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. J Acquir Immune Defic Syndr. 2009;51:65-71. [PMID: 19282780]
37. Bakanda C, Birungi J, Mwesigwa R, Nachega JB, Chan K, Palmer A, et al. Survival of HIV-Infected Adolescents on Antiretroviral Therapy in Uganda: Findings from a Nationally Representative Cohort in Uganda. PLoS One. 2011; 6:e19261. [PMID: 21559441]
38. Rawat R, Kadiyala S, McNamara PE. The impact of food assistance on weight gain and disease progression among HIV-infected individuals accessing AIDS care and treatment services in Uganda. BMC Public Health. 2010;10:316. [PMID: 20529283]
39. Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One. 2009;4:e5790. [PMID: 19495419]
40. Mugyenyi P, Walker AS, Hakim J, Munderi P, Gibb DM, Kityo C, et al; DART Trial Team. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet. 2010;375:123-31. [PMID: 20004464]
41. Jaffar S, Amuron B, Foster S, Birungi J, Levin J, Namara G, et al; Jinja Trial Team. Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial. Lancet. 2009;374:2080-9. [PMID: 19939445]
42. Muga R, Ferreros I, Langohr K, de Olalla PG, Del Romero J, Quintana M, et al; Spanish Multicenter Study Group of Seroconverters (GEMES). Changes in the incidence of tuberculosis in a cohort of HIV-seroconverters before and after the introduction of HAART. AIDS. 2007;21:2521-7. [PMID: 18025889]
43. Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, Cohen CR, et al; Partners in Prevention HSV/HIV Transmission Study Team. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375:2092-8. [PMID: 20537376]
44. Hecht R, Alban A, Taylor K, Post S, Andersen NB, Schwarz R. Putting it together: AIDS and the millennium development goals. PLoS Med. 2006;3: e455. [PMID: 17132054]
45. Mugyenyi P. Flat-line funding for PEPFAR: a recipe for chaos [Letter]. Lancet. 2009;374:292. [PMID: 19632493]